Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Badger Reformulates Sunscreens To Meet Nano-Free Demand

This article was originally published in The Tan Sheet

Executive Summary

Amid activist group and consumer concerns about the safety of nanoparticles in sunscreens, W.S. Badger Co. says it reformulated its sunscreen lineup with non-nanoparticles of zinc oxide while maintaining product efficacy.

You may also be interested in...



FDA Nanotech Guidance Takes Small Step Forward

FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.

FDA Nanotech Guidance Takes Small Step Forward

FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.

FDA Nanotech Guidance Takes Small Step Forward

FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105077

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel